Program

DOWNLOAD PROGRAM

 

Thursday,September 8th, 2016 - Afternoon

14.30 - 15.00
Introduction
A. Vannucchi(Florence, I), L. Dei (Florence, I),M. Calamai(Florence, I)

15.00 - 15.15
Welcome addresses
A. Casini (Florence, I)

15.15 - 16.00
Chairpersons: A. Vannucchi (Florence, I)
T. Barbui (Bergamo, I)
Opening Lecture Fitting MPN diagnosis within the WHO criteria

Session I: Seed and Soil

Chairpersons: R. Lemoli (Genoa, I), L. Pieri (Florence, I)
16.00 - 16.30

A. Migliaccio (New York, USA)
The stem cell of origin of MPN

16.30 - 17.00
S. Mèndez - Ferrer (Cambridge,UK)
The microenvironment of MPN

17.00 - 17.30
M.C. Le Bousse Kerdiles (Villejuif, FR)
Cytokines and inflammation in MPN

17.30 - 18.00
S. Constantinescu (Brussels, BE)
Receptors and signaling

18.00
Welcome Ceremony

Friday,September 9th, 2016 - Morning

Session II: The mutational landscape of MPN (I)

Chairpersons: G. Specchia (Bari, I), A.M. Vannucchi (Florence,I)

09.00 – 09.30
R. Kralovics (Wien, A)
The mutational landscape of MPN

09.30 – 10.00
W. Vainchenker (Villejuif, FR)
Calreticulin mutations: a new paradigm of disease?

10.00– 10.30
N. Cross (Southampton, UK)
Germline alleles that predispose to MPN

10.30 - 11.00
R. Skoda (Basel, CH)
Clonal complexity and clonal progression in MPN

11.00 - 11.30
Coffee break

Session III: The mutational landscape of MPN (II)

11.30 – 12.00
P.Guglielmelli (Florence, I)
Mutations and prognosis

12.00 – 12.30
J. Prchal (St Lake, US)
Clonal hematopoiesis of indeterminate potential

12.30 – 13.00
I. Roberts (Oxford, UK)
Transient myeloproliferative disorders

13.00 – 14.00
Buffet Lunch

Friday, September 9th, 2016 - Afternoon

Session IV: The path to Target therapy

Chairpersons: A. Bosi (Florence, I), A. Rambaldi (Bergamo, I)

14.00 - 14.30
A. Mullally (Boston, US)
Targets for targeted therapy

14.30 - 15.00
G. Barosi (Pavia, I)
How to best design novel clinical trials

15.00 - 15-30
F. Passamonti (Varese, I)
How to best select patients for clinical trials

15.30 - 16.00
J. J. Kiladjian (Paris, FR)
How to use at best JAK inihibitors

16.00 - 16.30
Coffee Break

16.30 - 17.00
A. Tefferi (Rochester, US)
Novel drugs outside JAK inhibitors

17.00 - 17.30
A.Reiter (Mannheim, DE)
Mastocytosis and eosinophilias

17.30 - 18.00
F. Lo Coco (Rome, I)
Target therapy: Lessons from acute leukemia

Saturday, September 10th, 2016 - Morning

Session V:Myelodysplastic syndromes and leukemia

Chairpersons : R. Foà (Rome, I),M. Cazzola (Pavia, I)

09.00 - 09-30
M. Cazzola (Pavia, I)
The mutational landscape of MDS

09.30 - 10.00
E.Solary (Paris, FR)
Mutations and targets in CMML

10.00 - 10.30
V.Santini (Florence, I)
Targeted agents for MDS

10.30 - 11.00
C. Mecucci (Perugia, I)
Germline alleles that predispose to leukemia

11.00 - 11.30
Coffee break

11.30 - 12.30
F.S. Mennini (Rome, I)
Lecture: Sustainable drug development and use in onco-hematology

12.30 - 13.30
General discussion and concluding remarks

13.30 - 14.30
Brunch

Promoted by
With the patronage of
Associazione Italiana per la Ricerca sul Cancro (AIRC)
AIRC
SIE (Società Italiana di Ematologia)
Società Italiana di Ematologia Sperimentale (SIES)
SIES
Gruppo Italiano Trapianti di Midollo Osseo (GITMO)
GITMO


Logo Avec

© Recent Advances in Understanding and Treating Myeloid Neoplasms 2016